Evaluation of clinical diagnostic criteria for neurofibromatosis 2

Neurology

Volumn 59, Issue 11, 2002, Pages 1759-1765

  Baser, Michael E ^d   Friedman, J M ^a   Wallace, A J ^b   Ramsden, R T ^c   Joe, H ^a   Evans, D G R ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b ST MARY S HOSPITAL   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CLINICAL MEDICINE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FAMILY HISTORY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; NEURILEMOMA; NEUROFIBROMATOSIS; PRIORITY JOURNAL;

EID: 0037058777     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000035638.74084.F4     Document Type: Article

References (33)

1. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800. Published erratum in Cell 1993;75:826.
2. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993;363:515-521.
3. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, fitness, and confirmation of maternal transmission effect on severity. J Med Genet 1992;29:841-846.
4. Evans DGR, Huson SM, Donnai D, et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992;84:603-618.
5. Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): Clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1996;52:450-461.
6. Mautner VF, Lindenau M, Baser ME, et al. The neuroimaging and clinical spectrum of neurofibromatosis 2. Neurosurgery 1996;38:880-885.
7. Rouleau GA, Wertelecki W, Haines JL, et al. Genetic linkage analysis of bilateral acoustic neurofibromatosis to a DNA marker on chromosome 22. Nature 1987;329:246-248.
8. National Institutes of Health Consensus Development Conference. Neurofibromatosis conference statement. Arch Neurol 1988;45:575-578.
9. Consensus Development Panel. National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. Arch Neurol 1994;51:201-207.
10. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-57.
11. Mosteller F, Tukey JW. Data Analysis and Regression, A Second Course in Statistics. Reading: Addison-Wesley, 1977.
12. Wu CL, Thakker N, Neary W, et al. Differential diagnosis of type 2 neurofibromatosis: Molecular discrimination of NF2 and sporadic vestibular schwannomas. J Med Genet 1998;35:973-977.
13. Evans DG, Lye R, Neary W, et al. Probability of bilateral disease in people presenting with a unilateral vestibular schwannoma. J Neurol Neurosurg Psychiatry 1999;66:764-767.
14. Mohyuddin A, Neary WJ, Wallace A, et al. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. J Med Genet 2002;39:315-322.
15. Kluwe L, Mautner VF. Mosaicism in sporadic neurofibromatosis 2 patients. Hum Mol Genet 1998;7:2051-2055.
16. Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T. Somatic mosaicism: A common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. Am J Hum Genet 1998;63:727-736.
17. Baser ME, Wallace AJ, Strachan T, Evans DGR. Clinical and molecular correlates of somatic mosaicism in neurofibromatosis 2. J Med Genet 2000;37:542-543.
18. Howitz MF, Johansen C, Tos M, Charabi S, Olsen JH. Incidence of vestibular schwannoma in Denmark, 1977-1995. Am J Otol 2000;21:690-694.
19. Baser ME, Friedman JM, Wallace A, Ramsden RT, Evans DGR. Evaluation of neurofibromatosis 2 diagnostic criteria in NF2 patients without bilateral vestibular schwannomas. Am J Hum Genet 2000;67(suppl 2):A359.
20. Iwata A, Kunimoto M, Inoue K. Schwann cell proliferation as the cause of peripheral neuropathy in neurofibromatosis-2. J Neurol Sci 1998;156:201-204.
21. Kilpatrick TJ, Hjorth RJ, Gonzales MF. A case of neurofibromatosis 2 presenting with a mononeuritis complex. J Neurol Neurosurg Psychiatry 1992;55:391-393.
22. Evans DGR, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999;81:496-499.
23. Trivedi R, Byrne J, Huson SM, Donaghy M. Focal amyotrophy in neurofibromatosis 2. J Neurol Neurosurg Psychiatry 2000;69:257-261.
24. Gijtenbeek JMM, Gabreëls-Festen AAWM, Lammens M, Zwarts MJ, van Engelen BGM. Mononeuropathy multiplex as the initial manifestation of neurofibromatosis type 2. Neurology 2001;56:1766-1768.
25. Sperfeld AD, Hein C, Schröder JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. Brain 2002;125:996-1004.
26. Mautner V-F, Tatagiba M, Guthoff R, Samii M, Pulst S-M. Neurofibromatosis 2 in the pediatric age group. Neurosurgery 1993;33:92-96.
27. MacCollin M, Mautner V-F. The diagnosis and management of neurofibromatosis 2 in childhood. Semin Pediatr Neurol 1998;5:243-252.
28. Evans DGR, Huson SM, Donnai D, et al. A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counseling. J Med Genet 1992;29:847-852.
29. Jacoby LB, MacCollin M, Louis DN, et al. Exon scanning for mutation of the NF2 gene in schwannomas. Hum Mol Genet 1994;3:413-416.
30. Zucman-Rossi J, Legoix P, Der Sarkissian H, et al. NF2 gene in neurofibromatosis type 2 patients. Hum Mol Genet 1998;7:2095-2101.
31. Kino T, Takeshima H, Nakao M, et al. Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 2001;6:441-454.
32. Ruttledge MH, Narod SA, Dumanski JP, et al. Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers. Neurology 1993;43:1753-1760.
33. Baser ME, Mautner V-F, Ragge NK, et al. Presymptomatic diagnosis of neurofibromatosis 2 using linked genetic markers, neuroimaging, and ocular examinations. Neurology 1996;47:1269-1277.